Atreon Orthopedics announced a merger with RenovoDerm, bringing together two companies focused on synthetic biomaterials for tissue repair and remodeling. The combined organization, Atreon Orthopedics, Inc., aims to expand its Autobiologic™ platform technology across orthopedic, trauma, sports medicine, reconstructive, foot and ankle, and complex wound applications.
The merger combines Atreon’s tendon-to-bone healing technologies with RenovoDerm’s synthetic wound reconstruction products. The companies said the integration creates a broader portfolio of synthetic biomaterial solutions designed to optimize tissue repair and remodeling while supporting long-term commercial growth.
According to the announcement, the combined business will focus on four primary strengths:
- A comprehensive platform of synthetic biomaterial solutions designed for ease of use.
- Expanded clinical indications across orthopedic, trauma, sports medicine, foot and ankle, reconstructive, and complex wound applications.
- A unified Autobiologic™ technology platform designed to address biologic challenges in tissue repair and remodeling.
- A strengthened commercial infrastructure intended to support scalable growth across procedures, specialties, and care settings.
The combined company said its synthetic scaffolds are engineered to optimize the cellular microenvironment, support native tissue remodeling, and improve long-term healing outcomes. RenovoDerm’s PHOENIX Wound Matrix®, which is designed for chronic and complex wounds, will complement Atreon’s bio-inductive scaffolds used in tendon-to-bone healing applications such as rotator cuff repair.
Atreon Orthopedics said the merger will also support expanded clinical evidence generation, accelerated product development, and broader commercial reach across surgical specialties.
KEY QUOTES:
“This merger accelerates our ability to transform how surgeons approach the complexities of achieving durable tissue repair. By combining Atreon’s leadership in tendon-to-bone healing with RenovoDerm’s advancements in complex wound reconstruction, we are creating a powerful platform that elevates performance, consistency and clinical versatility in a vast array of surgical applications.
Our shared vision is to move beyond traditional augmentation and toward true biologic orchestration. Traditional products often fail to address biologic gaps and industry shortfalls as surgeons seek a reliable solution that enables predictable, durable tissue repair without the risk of persistent inflammation or potential complications. Our Autobiologic portfolio offers a consistent and flexible solution to meet diverse surgical needs and enable broad market adoption. By uniting our teams and technologies, we are building a platform that supports surgeons across specialties and sets the stage for future innovation.”
Ronald Bracken, Chief Executive Officer, Atreon Orthopedics
